Ong Cheung-Ter, Sung Sheng-Feng, Wu Chi-Shun, Hsu Yung-Chu, Su Yu-Hsiang, Li Chen-Hsien, Hung Ling-Chien
Department of Neurology, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chia-Yi, Taiwan, ROC; Department of Nursing, Chung Jen Junior College of Nursing, Health Science and Management, Chia-Yi, Taiwan, ROC.
Department of Neurology, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chia-Yi, Taiwan, ROC.
J Chin Med Assoc. 2014 Apr;77(4):179-83. doi: 10.1016/j.jcma.2014.02.002. Epub 2014 Mar 20.
Early neurological improvement has been observed in patients with stroke receiving treatment with standard intravenous recombinant tissue plasminogen activator. However, the effectiveness of thrombolytic treatment and the risk of hemorrhagic transformation are not well understood in patients aged ≥ 80 years. In this study, we investigated the influence of age on early neurological improvement and hemorrhagic transformation rates in patients with stroke aged ≥ 80 years and receiving recombinant tissue plasminogen activator.
The study included 157 patients who received recombinant tissue plasminogen activator infusion at a teaching hospital. The National Institutes of Health Stroke Scale was used to evaluate stroke severity. Early neurological improvement was defined as an improvement of 8 or more points on this scale (compared with baseline) 24 hours after thrombolytic treatment. Neurological improvement was defined as an improvement of 8 or more points (compared with baseline) at discharge. Neurological deterioration was defined as an increase of 4 or more points (compared with baseline). Multivariate analysis was used to evaluate the associations among age, neurological improvement, and hemorrhagic transformation.
The rate of early neurological improvement was 36.9% (58/157 patients) and the rate of hemorrhagic transformation was 22.3% (35/157 patients). At discharge, the rate of neurological improvement was 50.9% (80/157 patients) and the rate of neurological deterioration was 13.4% (21/157 patients). There was no statistically significant difference between patients aged ≥ 80 years and those <80 years of age with respect to rates of early neurological improvement, neurological deterioration, or hemorrhagic transformation. Among patients ≥ 80 years, the rate of neurological improvement in those receiving thrombolytic treatment was higher than the rate in those patients not receiving thrombolytic treatment (58.8% vs. 14.1%, p < 0.01). We concluded that thrombolysis increases the rate of neurological improvement in patients aged ≥ 80 years.
In older patients, thrombolytic treatment increased the rate of neurological improvement compared with patients not receiving the treatment. The study showed that thrombolytic treatment may be beneficial for patients ≥80 years, but should be performed with extreme care.
在接受标准静脉注射重组组织型纤溶酶原激活剂治疗的中风患者中,已观察到早期神经功能改善。然而,对于80岁及以上的患者,溶栓治疗的有效性和出血转化的风险尚不清楚。在本研究中,我们调查了年龄对80岁及以上接受重组组织型纤溶酶原激活剂治疗的中风患者早期神经功能改善和出血转化率的影响。
该研究纳入了一家教学医院中157例接受重组组织型纤溶酶原激活剂输注的患者。采用美国国立卫生研究院卒中量表评估中风严重程度。早期神经功能改善定义为溶栓治疗24小时后该量表评分较基线提高8分或更多。神经功能改善定义为出院时较基线提高8分或更多。神经功能恶化定义为较基线增加4分或更多。采用多变量分析评估年龄、神经功能改善和出血转化之间的关联。
早期神经功能改善率为36.9%(58/157例患者),出血转化率为22.3%(35/157例患者)。出院时,神经功能改善率为50.9%(80/157例患者),神经功能恶化率为13.4%(21/157例患者)。在早期神经功能改善率、神经功能恶化率或出血转化率方面,80岁及以上患者与80岁以下患者之间无统计学显著差异。在80岁及以上的患者中,接受溶栓治疗的患者神经功能改善率高于未接受溶栓治疗的患者(58.8%对14.1%,p<0.01)。我们得出结论,溶栓治疗可提高80岁及以上患者的神经功能改善率。
在老年患者中,与未接受治疗的患者相比,溶栓治疗提高了神经功能改善率。该研究表明,溶栓治疗可能对80岁及以上的患者有益,但应极其谨慎地进行。